Navigating Advanced Prostate Cancer Treatment: Optimizing Novel Therapeutic Strategies for Managed Care Pharmacists

Program Description

Navigating the complex and rapidly evolving treatment landscape for prostate cancer presents significant challenges for managed care and oncology pharmacists. The disease is characterized by a wide range of prognoses, from indolent to highly aggressive, and is further complicated by significant disparities in diagnoses. From a managed care perspective, balancing the high cost of novel therapies against the need to provide timely access to effective, personalized care may present unique challenges. This session will review the latest therapeutic advancements in prostate cancer, with a focus on optimizing patient care and outcomes. Speakers will discuss the evolving role of second-generation anti-androgens, PARP inhibitors, and the use of molecular testing to personalize therapy. A key focus will be the role of the managed care pharmacist through an examination of the cost-effectiveness of advanced prostate cancer therapies and strategies to ensure equitable access and optimize therapeutic outcomes.

Target Audience: Managed Care Pharmacist, Oncology Pharmacist

Type of Activity: Application
Release date: November 7, 2025
Expiration date: November 7, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Investigate the evolving treatment landscape for prostate cancer, including the role of second-generation anti-androgens, PARP inhibitors, and the use of molecular testing in personalizing therapy to optimize patient outcomes.
2. Examine the latest clinical and safety evidence for new and emerging anti-androgens, PARPi, and PARPi/anti-androgen combinations used to treat prostate cancer.
3. Compare the cost-effectiveness of advanced prostate cancer treatments and strategies to optimize therapeutic access and outcomes in managed care settings.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-367-H01-P. The activity is available for CE credit through November 7, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Sherry L. Vogt, PharmD, BCOP, has no relevant financial relationships with ineligible companies to disclose.

Simone Ndujiuba, PharmD, BCOP, has the following relevant financial relationship with an ineligible company to disclose: Employee of PBM: Prime Therapeutics: Sr. Principal, Clinical Oncology Pharmacist.

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose.

Pharmacy Times® Editorial Staff— Aislinn Antrim

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms